| H01651 | |
| H number | H01651 |
| Name | Macular edema |
| Description | Macular edema is a common feature of many diseases of the retina, such as intraocular inflammation (uveitis), central or branch retinal vein occlusion, diabetic retinopathy and following cataract extraction. It is characterized by a retinal thickening in the macular area due to the breakdown of the blood-retinal barrier. Extracellular fluid accumulates in the intraretinal area or collects in the subretinal space. In more severe cases, it occurs as cystoid edema with the typical petaloid appearance, and is the leading cause of visual loss. New treatments for macular edema have emerged over the past decade, the most recent and efficacious of which have involved blockage of vascular endothelial growth factor (VEGF) by frequent intravitreal injection of pharmacologic agents. |
| Category | Nervous system disease |
| Network | - |
| Gene | - |
| Pathogen | - |
| Env factor | - |
| Carcinogen | - |
| Drug | Dexamethasone [DR:D00292] Aflibercept [DR:D09574] Ranibizumab [DR:D05697] Faricimab [DR:D11516] |
| Comment | - |
| Other DBs | ICD-11: 9B75.Y ICD-10: H35.8 MeSH: D008269 OMIM: 153880 |
| Reference | PMID:19668445 AUTHORS Rotsos TG, Moschos MM TITLE Cystoid macular edema. JOURNAL Clin Ophthalmol 2:919-30 (2008) DOI:10.2147/opth.s4033 PMID:21860693 AUTHORS Romero-Aroca P TITLE Managing diabetic macular edema: The leading cause of diabetes blindness. JOURNAL World J Diabetes 2:98-104 (2011) DOI:10.4239/wjd.v2.i6.98 PMID:27256304 AUTHORS Fardeau C, Champion E, Massamba N, LeHoang P TITLE Uveitic macular edema. JOURNAL Eye (Lond) 30:1277-1292 (2016) DOI:10.1038/eye.2016.115 PMID:27330464 AUTHORS Andreoli MT, Pinnolis M, Kieser T, Sun J, Andreoli CM TITLE Feasibility and efficacy of a mass switch from ranibizumab (Lucentis) to bevacizumab (Avastin) for treatment of neovascular age-related macular degeneration. JOURNAL Digit J Ophthalmol 21:1-17 (2015) DOI:10.5693/djo.01.2015.04.002 |